Mucopolysaccharidosis type IIIA (MPS IIIA) occurs due to the deficiency of lysosomal enzyme heparan-N-sulfatase (sulfamidase), which is caused by mutations in the SGSH gene. Aim. To identify the characteristics of biochemical diagnosis of MPS IIIA and determine the prevalence of major mutations R74C and R245H in the SGSH gene in Ukrainian patients. Methods. After all the required phases of laboratory diagnosis of this disease, the diagnosis of MPS IIIA was confirmed in 12 patients from 12 families. The level of sulfamidase activity in leukocytes did not exceed 36 % of the control in all patients. Due to very low sulfamidase activity in leukocytes it is sometimes difficult to interpret the results of the analysis which may lead to false-negative or false-positive diagnosis of MPS IIIA. Results. The analysis of the results of molecular investigation of the patients' samples showed that the incidence of mutation R74C was 17/24 (70.8 %), the incidence of mutation R245H was 2/24 (8.3 %). The total incidence of major mutations R74S and R245H among the patients with MPS IIIA in Ukraine was the highest amongEuropean countries -11 out of 12 patients, these mutations were found in at least one allele. Conclusions. Given very high prevalence of major mutations R74S and R245H in the SGSH gene among the patients with MPS IIIA in Ukraine -79.1 % -it is appropriate to have the screening of mutations in the diagnostic algorithm along with the definition of biochemical sulfamidase activity to prevent false-negative or false-positive diagnosis of Sanfilippo syndrome A.
Die durch Kondensationen der Benzodithioliumperchlorate (I) mit den o‐Hydroxybenzaldehyden (II) dargestellten Hydroxystyrole (III) gehen unter der Einwirkung von NH3 in die Spiroverbindungen (IV) (Ausbeute 35‐80%) über.
Mucopolysaccharidosis type III or Sanfilippo syndrome (MIM # 252900) is a rare hereditary autosomal-recessive metabolic disorder, which occurs due to the deficiency of heparan-N-sulfatase enzyme (EC 3.10.1.1). Aim. To identify the whole spectrum of mutations in SGSH gene in Ukrainian patients with MPS III A. Methods. RFLP-analysis, SSCP method, sequencing. Results. We have identified 100 % (42/42) mutant alleles of SGSH gene in 23 patients (two probands had siblings with identical genotypes) with MPS III A from 21 Ukrainian family. The range of mutations in SGSH gene in Ukrainian patients with MPS III A is represented with 7 known missence-mutations , R74C, R245H, T271M, E292K, S298P, E369K, N389K and 2 single nucleotide deletions, c.1080delC and c.1135delG. We identified three new mutations in the SGSH gene: a missence-mutation G149R,a deletion c.216delC, and a deletion of 27 bp TCC^348CTCctgccggcgctggaggccg agcccctcTGGGCCACC. Conclusions. The data obtained may be useful for molecular-genetic analysis of Ukrainian patients with MPS III A.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.